Maria Curcio Bishop

Interests

Teaching

1. Graduate medical education2. Post-graduate hematology/oncology education3. Medical ethics and palliative and supportive care4. Global cancer education

Research

1. Central nervous system malignancies2. Palliative and supportive care3. Global cancer education

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Bishop, M. C. (2020). The Veterans Health Administration's Contribution to Cancer Education.. Journal of cancer education : the official journal of the American Association for Cancer Education, 35(1), 1-2. doi:10.1007/s13187-019-01679-z
• Bishop, M. (2019). An Opportunity to Share. Journal of Cancer Education, 34, 628.
• Bishop, M. (2019). An Opportunity to Share. Journal of Cancer Education, Published Online. doi:DOI: 10.1007/s13187-019-01584-5
• Bishop, M., Veto, J., Michael, A., & Hamilton, J. (2019). The Art of Journal Writing and Reviewing: Keys to Success. Journal of Cancer Education, Suppl1: S13, 34.
• Bishop, M. (2018). Gifts from the Past. Journal of Cancer Education, 1425-1426. doi:10.1007/s13187-018-1425-6.
  More info

  Editorial
• Bishop, M. (2018). Mentorship in Medicine and other Health Professions. Journal of Cancer Education, 1360-1366. doi:10.1007/s13187-018-1360-6.
  More info

  Review Article
• Bishop, M., & Szumacher, E. (2014). Career Counseling for Medical Oncology and Radiation Oncology Postgraduate Trainees. Journal of Cancer Education, 29(s1).
• Rogowitz, E., Babiker, H. M., Kanaan, M., Millius, R. A., Ringenberg, Q. S., & Bishop, M. (2014). Neuroblastoma of the elderly, an oncologist's nightmare: case presentation, literature review and SEER database analysis. Experimental hematology & oncology, 3, 20.
  More info

  Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, and End Results (SEER) database analysis in the USA between 1973-2007 that revealed only 35 elderly patients (>60 years of age) with neuroblastoma of whom only 2 patients had primary mediastinal neuroblastoma. There is a paucity of treatment and survival outcomes data for the elderly owing to the rarity of neuroblastoma in this population. Currently there are no standard guidelines or protocols for treatment of adult neuroblastoma. We report a rare and challenging case of an 86-year old patient presenting with mediastinal neuroblastoma and syndrome of inappropriate antidiuretic hormone secretion (SIADH) successfully treated with resection. Herein, we also provide a review of the literature and updated survival data on neuroblastoma based on results of our SEER database review.
• Taverna, J. A., Babiker, H. M., Yun, S., Bishop, M. C., Lau-Braunhut, S., Meyer, P. N., & Enzler, T. (2014). The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomarker research, 2(1), 23.
  More info

  Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells. These phenomena are mediated by humoral factors secreted by tumor cells or by tumor mediated immune responses. Among paraneoplastic syndromes, chronic intestinal pseudo-obstruction (CIPO) is rare and represents a particularly difficult clinical challenge. Paraneoplastic CIPO is a highly morbid syndrome characterized by impaired gastrointestinal propulsion with symptoms and signs of mechanical bowel obstruction. Clinical outcomes of paraneoplastic CIPO are often deleterious. The current standard of care for the management of CIPO includes supportive treatment with promotility and anti-secretory agents. However, the majority of patients with CIPO eventually require the resection of the non-functioning gut segment. Here, we present a 62-year-old patient with anti-Hu antibody associated paraneoplastic CIPO and underlying small cell lung cancer who underwent treatment with cisplatin and etoposide. Herein, we discuss diagnosis, prognosis, proposed mechanisms, treatment options, and future potential therapeutic strategies of paraneoplastic CIPO.
• Agarwal, A., Larsen, B. T., Buadu, L. D., Dunn, J., Crawford, R., Daniel, J., & Bishop, M. C. (2013). Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection. Case reports in oncological medicine, 2013, 496351.
  More info

  Giant-cell tumor of the bone (GCTB) is a rare neoplasm that affects young adults. The tumor is generally benign but sometimes can be locally aggressive. There are no standardized approaches to the treatment of GCTB. Recently, the RANKL inhibitor denosumab has shown activity in this tumor type. We present the case of a young female who presented with locally advanced disease and was successfully managed with the neoadjuvant use of denosumab allowing for surgical resection of the tumor that was previously deemed unresectable. Following surgery, the patient is being managed with continued use of denosumab as 'maintenance,' and she continues to be free of disease. Our case highlights a novel approach for the management of locally advanced and aggressive giant cell tumor of the bone.
• Badger, T. A., Segrin, C., Figueredo, A. J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., & Bishop, M. (2013). Who benefits from a psychosocial counselling versus educational intervention to improve psychological quality of life in prostate cancer survivors?. Psychology & health, 28(3), 336-54.
  More info

  We examined selected survivor characteristics to determine what factors might moderate the response to two psychosocial interventions.
• Larsen, B. T., Bishop, M. C., Hunter, G. C., & Renner, S. W. (2013). Low-grade, metastasizing splenic littoral cell angiosarcoma presenting with hepatic cirrhosis and splenic artery aneurysm. International journal of surgical pathology, 21(6), 618-26.
  More info

  The behavior of littoral cell neoplasms ranges from benign (littoral cell angioma, LCA) to highly malignant (angiosarcoma). Two unusual cases of low-grade metastatic littoral cell angiosarcoma (LCAS) have been reported with late recurrence and bulky metastases. We present the third case of this rare neoplasm in a 38-year-old man with cirrhosis and a large splenic artery aneurysm, without extrasplenic masses. The spleen showed nodules resembling LCA, immunoreactive for CD31, factor VIII, CD68, and CD163 but not CD8 or CD34. Also present were solid areas of immunophenotypically identical bland spindle cells, although lighter CD31 immunostaining distinguished them from LCA-like angiomatous channels. Similar cells diffusely infiltrated the cirrhotic liver. After splenectomy, pancytopenia resolved, and he is asymptomatic 19 months later. Low-grade LCAS is a previously unreported cause of cirrhosis and may metastasize without forming masses. In cases of LCA, CD31 immunohistochemistry may facilitate detection of LCAS and indicate metastatic potential.
• Badger, T. A., Segrin, C., Figueredo, A. J., Harrington, J., Sheppard, K., Passalacqua, S., Pasvogel, A., & Bishop, M. (2011). Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 20(6), 833-44.
  More info

  The primary purpose was to test the effectiveness of two telephone-delivered psychosocial interventions for maintaining and improving quality of life (QOL) (psychological, physical, social, and spiritual well-being) among 71 prostate cancer survivors and the 70 intimate or family partners who were supporting them in their recovery.
• Nguyen, N. P., Bishop, M., Borok, T. J., Welsh, J., Hamilton, R., Cohen, D., Nguyen, L. M., & Vincent, V. (2010). Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer research, 30(3), 953-61.
  More info

  Standard of care for locally advanced non-small cell lung cancer has been concurrent chemoradiation. However, optimal chemotherapy regimen, radiation therapy dose and treatment volume have not been clearly defined despite 30 years of controlled clinical trials. This review analyzes survival and failure pattern reported from randomized studies of chemoradiation for non-small cell lung cancer. Despite introduction of new chemotherapy agents, survival remained poor; rates of both locoregional failures and distant metastasis remained high. The current radiation dose appears insufficient to reliably establish local control. Stereotactic body radiotherapy may allow radiation dose escalation and should be tested in future clinical trials.
• Dayani, P. N., Bishop, M. C., Black, K., & Zeltzer, P. M. (2004). Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer. Journal of neuro-oncology, 67(3), 367-77.
  More info

  Iron homeostasis is crucial to normal cell metabolism, and its deficiency or excess is associated with numerous disease states. The association of increased iron load with cancer may be due to several factors including free radical production, reduction of the body's protective mechanism to combat oxidative stress, inhibition of immune systems, inhibition of essential nutrient functions, facilitation of cancer growth, suppression of antitumor actions of macrophages, and lowering of the ratio of T4-T8 positive lymphocytes. Antiproliferative effects of desferoxamine (DFO) both in vitro and in vivo are mediated by an intracellular pool of iron that is necessary for DNA synthesis rather than prevention of iron uptake from transferrin. Several clinical studies have shown it to have antitumor activity in the treatment of neuroblastoma, leukemia, bladder carcinoma, and hepatocellular carcinoma. Human neural tumor cells are susceptible to the effects of DFO. Continued study of DFO is necessary to further elucidate its antineoplastic profile and its use as an adjunct to current chemotherapy regimens. Given the lack of satisfactory treatment of central nervous system neoplasms, DFO could serve as an important tool in the management of such cancers.
• Bishop, M. C., Gores, F. A., Stempel, J., Torrington, P., Tynan, C., Jaskar, D., & Garewal, H. S. (2000). A collaborative end-of-life care curriculum. American Journal of Hospice and Palliative Medicine®, 17(2), 137-140. doi:10.1177/104990910001700214

Presentations

• Bishop, M. (2019, May). Journal of Cancer Education: Opportunities for Mentorship. European Association for Cancer Education 32nd Annual Scientific Meeting. Porto, Portugal: European Association for Cancer Education.
  More info

  I presented a workshop that addressed mentoring opportunities journal authors and reviewers.
• Bishop, M. (2019, September). Insights into Authorship and the Peer Review Process. International Cancer Education Workshop. Salt Lake City, Utah: International Cancer Education.
• Bishop, M. (2018, October, 2018). Developing a distance mentoring program with an international perspective impacting inter-professional global cancer training and care.. 2018 World Cancer Congress, UICC. Kuala Lumpur, Malaysia: Internation Union for Cancer Control.
  More info

  Accepted AbstractPresented at the World Cancer Congress

Others

• Bishop, M. (2020, January). The Veterans Health Administration's Contribution to Cancer Education. Journal of Cancer Education.
  More info

  Editorial https://doi.org/10.1007/s13187-019-01679-z